CD19 Antibody (CVID3/429), Novus Biologicals™

CD19

0.2 mg/mL

Flow Cytometry, SDS-Page, Immunofluorescence

Unconjugated

Mouse

Adaptive Immunity, Cytokine Research, Immunology, Innate Immunity, Mesenchymal Stem Cell Markers, Signal Transduction, Stem Cell Lines, Stem Cell Markers

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

930

Recombinant human CD19 protein

Primary

Store at 4C.

95 kDa

CVID3/429

Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, SDS-Page, Immunofluorescence 0.5 - 1.0 ug/ml

Monoclonal

Purified

RUO

Human, Monkey, Primate

B4, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CD19 antigen, CD19 molecule, CVID3, Differentiation antigen CD19, MGC12802, T-cell surface antigen Leu-12

CD19

IgG1 κ

Protein A or G purified

CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms